

BIOCON GROUP

FACT SHEET

December - 2014

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		(Rs. Crores)
	Dec 31, 2014	March 31, 2014
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	3,194	2,927
	3,294	3,027
Minority interest	69	82
Non-current liabilities		
(a) Long-term borrowings	797	606
(b) Deferred tax liability (net)	42	45
(c) Other long-term liabilities	633	603
(d) Long-term provisions	10	8
	1,482	1,262
Current liabilities		
(a) Short-term borrowings	369	244
(b) Trade payables	480	347
(c) Other current liabilities	424	612
(d) Short-term provisions	71	177
	1,344	1,380
TOTAL	6,189	5,751
ASSETS		
Non-current assets		
(a) Fixed assets	3,137	2,719
(b) Goodwill	179	12
(c) Non-current investments	65	65
(d) Long term loans and advances	325	269
(e) Other non-current assets	149	47
(f) Deferred tax asset	10	-
	3,865	3,112
Current assets		
(a) Current Investments	302	700
(b) Inventories	510	377
(c) Trade receivables	691	600
(d) Cash and cash equivalents	586	804
(e) Short term loans and advances	148	82
(f) Other current assets	87	76
	2,324	2,639
TOTAL	6,189	5,751

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	9M FY 15	9M FY 14	Variance
INCOME			
Biopharmaceuticals	1,645	1,604	3%
Biopharma *	1,314	1,305	1%
Branded formulations - India	331	299	11%
Contract research	584	526	11%
Total Sales	2,229	2,130	5%
Other income	59	57	4%
Total Revenue	2,288	2,187	5%
EXPENDITURE			
Material & Power costs	1,046	1,016	3%
Staff costs	367	317	16%
Research & Development **	113	102	11%
Other expenses	214	202	6%
Manufacturing, staff & other expenses	1,740	1,637	
EBITDA	548	550	0%
Interest & Finance charges	10	1	
Depreciation & Amortisation	162	150	9%
PBT	376	399	-6%
Taxes	64	88	
NET PROFIT BEFORE MINORITY INTEREST	312	311	0%
Minority interest	16	11	
NET PROFIT FOR THE PERIOD	296	300	-2%
EPS Rs.	14.8	15.0	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
Licensing Income	38	15	
<i>** Gross Research & Development expenses</i>			
	176	114	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 15	Q3 FY 14	Variance
<u>INCOME</u>			
Biopharmaceuticals	541	517	5%
Biopharma *	436	418	4%
Branded formulations - India	105	99	6%
Contract research	220	183	20%
Total Sales	761	700	9%
Other income	18	19	-2%
TOTAL REVENUE	779	719	8%
<u>EXPENDITURE</u>			
Material & Power costs	360	338	7%
Staff costs	126	107	18%
Research & Development **	47	20	134%
Other expenses	76	67	14%
Manufacturing, staff & other expenses	609	532	
EBITDA	170	187	-10%
Interest & Finance charges	5	-	
Depreciation & Amortisation	56	51	10%
PBT	109	136	-20%
Taxes	11	26	
NET PROFIT BEFORE MINORITY INTEREST	98	110	-12%
Minority interest	7	5	
NET PROFIT FOR THE PERIOD	91	105	-13%
EPS Rs.	4.6	5.3	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	10	4	
** Gross Research & Development expenses	66	23	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 15	Q2 FY 15	Variance
<u>INCOME</u>			
Biopharmaceuticals	541	558	-3%
Biopharma *	436	442	-1%
Branded formulations - India	105	116	-10%
Contract research	220	192	14%
Total Sales	761	750	2%
Other income	18	23	-22%
	779	773	1%
<u>EXPENDITURE</u>			
Material & Power costs	360	351	3%
Staff costs	126	125	1%
Research & Development **	47	35	33%
Other expenses	76	74	4%
Manufacturing, staff & other expenses	609	585	
EBITDA	170	188	-10%
Interest & Finance charges	5	5	
Depreciation & Amortisation	56	54	4%
PBT	109	129	-16%
Taxes	11	22	
NET PROFIT BEFORE MINORITY INTEREST	98	107	-9%
Minority interest	7	5	
NET PROFIT FOR THE PERIOD	91	102	-11%
EPS Rs.	4.6	5.1	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	10	9	
** Gross Research & Development expenses	66	56	